Most Read Articles
Saras Ramiya, 15 Apr 2017
After being introduced to Malaysia 10 years ago, Bio-Oil has established itself as a staple skincare brand.
Jenny Ng, 05 Aug 2015
Concerns emerge over combining antidepressants with non-steroidal anti-inflammatory drugs (NSAIDs) as a study shows an increased risk of intracranial haemorrhage (ICH) in these patients. 
Debra Kennedy, 01 Jun 2014

Pregnant women do not need to suffer unnecessary pain or potentially dangerous fever for fear of their taking medications that may be harmful to their unborn baby. Healthcare providers should be confident when prescribing appropriate treatment to such women during pregnancy.

Harriet Pugsley, MB ChB, MRCOG; Judith Moore, MRCOG, 01 Aug 2013

Most women presenting with complications in early pregnancy are assessed, diagnosed and managed at early pregnancy assessment units (EPAUs). These units aim to provide thorough assessments, access to specialist investigations (scan, human chorionic gonadotrophin [hCG]), a rapid turnaround of results, and co-ordination of further management.

Mixed outpatient-inpatient model safe, cost-effective for multiple myeloma

03 Aug 2017

The adoption of a novel mixed outpatient-inpatient model has been shown to be cost-effective, safe and feasible for multiple myeloma, according to a recent study.

Researchers implemented a mixed outpatient-inpatient autologous stem cell transplantation at an institution to achieve financial benefit without compromising safety. Eligible patients were given melphalan in the clinic the day prior to being admitted for peripheral blood stem cell reinfusion in a hospital where they stay until recovery of myelosuppression.

A total of 19 patients received high-dose melphalan prior to autologous stem cell transplantation in the year since implementing the mixed model. Of these, 18 successfully received melphalan in the outpatient clinic with admission to the hospital on day zero for infusion of stem cells. No adverse event occurred in any patient on the day or evening of chemotherapy or required early admission.

The institution managed to save an average estimated cost of over $2,000 per patient with the implementation of the mixed model. When comparing the cost of the chemotherapy drug, melphalan, from the year before and the year after the implementation of the mixed model, the total annual cost saving was about $90,000 or 53 percent of the previous year’s expenditure.

“Although administration of chemotherapy prior to autologous stem cell transplantation in the outpatient setting has been reported as safe and cost-effective, many limitations exist with previously reported methods of transitioning out of the hospital ward,” researchers noted. “Specifically, lack of a caregiver and distance from treatment facility are key factors particularly in rural settings.”

Such limitations prevented institutions from transitioning the transplant process, or even portions of it, to the outpatient setting despite the known benefits, they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Saras Ramiya, 15 Apr 2017
After being introduced to Malaysia 10 years ago, Bio-Oil has established itself as a staple skincare brand.
Jenny Ng, 05 Aug 2015
Concerns emerge over combining antidepressants with non-steroidal anti-inflammatory drugs (NSAIDs) as a study shows an increased risk of intracranial haemorrhage (ICH) in these patients. 
Debra Kennedy, 01 Jun 2014

Pregnant women do not need to suffer unnecessary pain or potentially dangerous fever for fear of their taking medications that may be harmful to their unborn baby. Healthcare providers should be confident when prescribing appropriate treatment to such women during pregnancy.

Harriet Pugsley, MB ChB, MRCOG; Judith Moore, MRCOG, 01 Aug 2013

Most women presenting with complications in early pregnancy are assessed, diagnosed and managed at early pregnancy assessment units (EPAUs). These units aim to provide thorough assessments, access to specialist investigations (scan, human chorionic gonadotrophin [hCG]), a rapid turnaround of results, and co-ordination of further management.